EN
HI
Senores Pharmaceuticals Share price
SENORES
1475.7
53.50 (3.76%)NSE
BSE
Last updated on 11 Aug, 2026 | 15:55 IST
Senores Pharmaceuticals share price chart
Senores Pharmaceuticals Share Key Metrics
Volume
4.17 L
Market Cap
6796.13 CR
LTQ@LTP
20@1475.70
ATP
1455.46
Var Margin
20.68 %
Circuit Range
1137.8-1706.6
Delivery %
51.56 %
Value
60.76 CR
ASM/GSM
No
Market Lot
1
Summary
SENORES stock price is ₹1475.7 as of 12 Aug, 2026. The stock intraday movement has stayed between ₹1410.80 and ₹1496.30, while Senores Pharmaceuticals share price 52 week high low is ₹632.05 & ₹1509.80.
In terms of trading activity, SENORES share price has recorded a volume of 4,17,444 shares. The Senores Pharmaceuticals has a market cap of ₹46053588. The stock’s Average Traded Price (ATP) stands at ₹1455.46, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 20 @ ₹1475.70.
The Senores Pharmaceuticals upper circuit limit is ₹1706.60 & The Senores Pharmaceuticals lower circuit limit is ₹1137.80, with a Value of ₹60.76 CR. The Delivery Percentage for the day is 51.56%.
Additionally, the share currently falls under the No framework, and trades with a market lot size of ₹1.
Senores Pharmaceuticals Resistance and Support
Pivot 1395.1
Resistance
First Resistance
1465.1
Second Resistance
1508
Third Resistance
1578
Support
First Support
1352.2
Second Support
1282.2
Third Support
1239.3
Senores Pharmaceuticals Shareholding Pattern
View More- 2024-25
- 2025-26
- 2026-27
Total Promoters
Segment
Percent
Total Promoters
45.82%
Mutual Fund
6.56%
Insurance
1.62%
Foreign Institutional Investors
6.62%
Domestic Institutional Investors
1.59%
Retail
37.79%
Others
0%
Total Promoters
MAR '26
45.82%
JUN '26
45.82%
Senores Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-07-27 | Quarterly Results |
| 2026-05-14 | Audited Results |
| 2026-01-20 | Quarterly Results & Others |
| 2026-01-07 | Others |
| 2025-11-06 | Quarterly Results |
| 2025-07-23 | Quarterly Results & Others |
| 2025-05-15 | Audited Results |
| 2025-01-23 | Quarterly Results & Others |
Senores Pharmaceuticals News
Senores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Senores Pharmaceuticals' shareholders approved all 8 postal ballot resolutions. Key approvals include enhancing inter-corporate loan/guarantee limits under Sections 185 and 186, and adjusting the utilization terms and timeline for IPO proceeds. These approvals provide increased financial and operational flexibility.
Aug 04 2026 17:51:33
Senores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Senores Pharmaceuticals' shareholders approved all 8 postal ballot resolutions. Key approvals include enhancing inter-corporate loan/guarantee limits under Sections 185 and 186, and adjusting the utilization terms and timeline for IPO proceeds. These approvals provide increased financial and operational flexibility.
Aug 04 2026 17:48:44
Senores Pharmaceuticals Ltd - 544319 - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On June 30, 2026
Senores Pharma filed its Q1 FY27 statement on IPO fund utilization, reporting an ongoing delay in deploying Rs.107 crore allocated for its Havix manufacturing facility. The company is seeking shareholder approval for variation in the object. Minor reallocations of unutilized funds were also reported across other objectives.
Jul 27 2026 17:40:58
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Senores Pharma released its Q1 FY27 IPO fund utilization report, indicating a Rs. 65.02 crore re-allocation of funds from the Atlanta sterile injections facility project to other subsidiary capital expenditure needs. Delays in the Atlanta project are attributed to geo-political issues, requiring shareholder approval for the revised plan and extended timeline to Q4 FY28.
Jul 27 2026 17:32:10
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Senores Pharma reported robust Q1 FY27 results with consolidated revenue of Rs.180 crs, marking a 36% YoY growth. Net profit surged 56% to Rs.31 crs, alongside an 87% increase in EBITDA driven by margin expansion.
Jul 27 2026 15:47:23
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting
Senores Pharmaceuticals announced robust Q1 FY27 consolidated financial results with revenue growing 36% YoY to ₹180 cr and net profit up 56% YoY to ₹31 cr. The board also appointed Ms. Anjali Shah as Assistant VP-Finance (SMP) effective July 27, 2026.
Jul 27 2026 15:21:42
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Intimation for Considering And Approving The Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter Ended June 30, 2026 And To Transact Other Business Matters
Senores Pharmaceuticals announced its board will meet on July 27, 2026, to consider and approve the Q1 FY27 financial results. The meeting will also transact other business matters.
Jul 21 2026 15:58:18
Read More
Senores Pharmaceuticals Management
| Name | Position |
|---|---|
| Vinay Kumar Mishra | Company Secretary & Compliance Officer |
| Swapnil Jatinbhai Shah | Managing Director |
Senores Pharmaceuticals Similar Stocks
Yatharth Hospital & Trauma Care Services Ltd.
865.70
-33.05 (3.68%)
Sanofi India Ltd.
3303.20
-23.80 (0.72%)
Nephrocare Health Services Ltd.
712.30
14.60 (2.09%)
Kovai Medical Center & Hospital Ltd.
5865.50
-296.50 (4.81%)
Aarti Pharmalabs Ltd.
883.70
60.70 (7.38%)
FDC Ltd.
360.90
0.55 (0.15%)
Orchid Pharma Ltd.
1078.55
-0.60 (0.06%)
Innova Captab Ltd.
1018.90
52.80 (5.47%)
Supriya Lifescience Ltd.
851.00
-71.85 (7.79%)
Bliss GVS Pharma Ltd.
494.05
14.25 (2.97%)
Senores Pharmaceuticals FAQs
The Buying Price of Senores Pharmaceuticals share is 1475.7 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Senores Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Senores Pharmaceuticals, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Senores Pharmaceuticals shares is 51.82. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Senores Pharmaceuticals shares is 6.79. Useful to assess the stock's value relative to its book value.
To assess Senores Pharmaceuticals’s valuation compare Sector P/E, P/B which are 64.83 & 3.28 with sector averages, along with growth rates and financial metrics.
The Market Cap of Senores Pharmaceuticals is 6796.13 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Senores Pharmaceuticals share price is 1509.80 & 632.05. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Senores Pharmaceuticals belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Invest in SENORES
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC